Gary Elfring

9.4k total citations · 1 hit paper
93 papers, 5.9k citations indexed

About

Gary Elfring is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gary Elfring has authored 93 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 26 papers in Oncology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gary Elfring's work include Muscle Physiology and Disorders (40 papers), Cancer therapeutics and mechanisms (14 papers) and Cystic Fibrosis Research Advances (9 papers). Gary Elfring is often cited by papers focused on Muscle Physiology and Disorders (40 papers), Cancer therapeutics and mechanisms (14 papers) and Cystic Fibrosis Research Advances (9 papers). Gary Elfring collaborates with scholars based in United States, United Kingdom and France. Gary Elfring's co-authors include Langdon L. Miller, Paula K. Locker, Leonard B. Saltz, Nicoletta Pirotta, John V. Cox, Lee S. Rosen, Charles D. Blanke, Malcolm J. Moore, Stephen P. Ackland and Jean A. Maroun and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Gary Elfring

87 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

2000 2.4k citations Paula K. Locker, Gary Elfring et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary Elfring United States	27	3.1k	2.4k	1.5k	1.0k	813	93	5.9k
Langdon L. Miller United States	29	4.0k 1.3×	2.5k 1.0×	1.8k 1.2×	1.0k 1.0×	807 1.0×	65	7.6k
Mario Scartozzi Italy	44	3.7k 1.2×	1.7k 0.7×	2.1k 1.4×	953 0.9×	834 1.0×	343	6.4k
Francesco Cognetti Italy	46	5.0k 1.6×	2.4k 1.0×	2.3k 1.5×	226 0.2×	826 1.0×	221	8.5k
Ying‐Hong Shi China	45	1.8k 0.6×	3.1k 1.3×	750 0.5×	750 0.7×	953 1.2×	191	6.8k
John Hamm United States	22	4.0k 1.3×	1.1k 0.5×	1.6k 1.1×	329 0.3×	624 0.8×	74	5.2k
Evaristo Maiello Italy	38	3.7k 1.2×	1.7k 0.7×	1.7k 1.1×	539 0.5×	834 1.0×	267	5.8k
Tsu-Yi Chao Taiwan	31	2.3k 0.7×	1.5k 0.6×	2.0k 1.3×	399 0.4×	285 0.4×	102	4.4k
Donald P. Lawrence United States	44	6.7k 2.1×	3.1k 1.3×	1.8k 1.2×	129 0.1×	448 0.6×	161	8.9k
Hiromichi Ito Japan	37	2.7k 0.9×	1.1k 0.5×	1.6k 1.0×	949 0.9×	2.1k 2.6×	267	5.5k
Matthias Anthuber Germany	29	1.5k 0.5×	905 0.4×	1.0k 0.7×	341 0.3×	1.5k 1.8×	156	3.9k

Countries citing papers authored by Gary Elfring

Since Specialization

Citations

This map shows the geographic impact of Gary Elfring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Elfring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Elfring more than expected).

Fields of papers citing papers by Gary Elfring

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Elfring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Elfring. The network helps show where Gary Elfring may publish in the future.

Co-authorship network of co-authors of Gary Elfring

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Elfring. A scholar is included among the top collaborators of Gary Elfring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Elfring. Gary Elfring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McDonald, Craig M., Lee‐Jen Wei, Gary Elfring, et al.. (2019). Preservation of Function over time as Measured by North Star Ambulatory Assessment in Ambulatory Boys with Nonsense Mutation Muscular Dystrophy Treated with Ataluren (S51.004). Neurology. 92(15_supplement). 1 indexed citations

Shieh, Perry B., Joseph McIntosh, Marcio Ferreira de Souza, et al.. (2018). Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial. Muscle & Nerve. 58(5). 639–645. 41 indexed citations

McDonald, Craig M., K. Bushby, M. Tulinius, et al.. (2016). Ataluren: An Overview of Clinical Trial Results in Nonsense Mutation Duchenne Muscular Dystrophy (P3.162). Neurology. 86(16_supplement). 2 indexed citations

Campbell, Craig, Perry B. Shieh, Thomas Sejersen, et al.. (2016). Safety and Tolerability of Ataluren in a Phase 3 Study of Patients with Nonsense Mutation Duchenne Muscular Dystrophy (P3.164). Neurology. 86(16_supplement). 2 indexed citations

Muntoni, Francesco, Xiaohui Luo, Gary Elfring, et al.. (2016). Results of North Star ambulatory assessments in the phase 3 ataluren confirmatory trial in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD). Neuromuscular Disorders. 26. S154–S155. 2 indexed citations

Finkel, Richard S., Kevin M. Flanigan, Brenda Wong, et al.. (2013). Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy. PLoS ONE. 8(12). e81302–e81302. 172 indexed citations

Wilschanski, Michael, L.L. Miller, David Shoseyov, et al.. (2011). Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. European Respiratory Journal. 38(1). 59–69. 151 indexed citations

Kerem, Eitan, Michael Wilschanski, Thea Pugatsch, et al.. (2011). Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis. Journal of Cystic Fibrosis. 10(3). 193–200. 11 indexed citations

Sermet‐Gaudelus, Isabelle, K. De Boeck, Georges Casimir, et al.. (2010). Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 182(10). 1262–1272. 184 indexed citations

10.

Finkel, Richard S., Brenda Wong, K. Bushby, et al.. (2010). P3.51 Results of a Phase 2b, dose-ranging study of ataluren (PTC124®) in nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD). Neuromuscular Disorders. 20(9-10). 656–657. 12 indexed citations

11.

McDonald, Craig M., Erik Henricson, Jay J. Han, et al.. (2009). The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle & Nerve. 41(4). 500–510. 283 indexed citations

12.

McDonald, Craig M., Erik Henricson, Richard T. Abresch, et al.. (2009). M.P.3.03 6-minute walk test in Duchenne muscular dystrophy: Longitudinalobservations. Neuromuscular Disorders. 19(8-9). 601–602. 2 indexed citations

13.

Reha, A., Gary Elfring, Richard S. Finkel, et al.. (2008). T.P.5.01 Phase 2b Study of PTC124 in Duchenne/Becker muscular dystrophy (DMD/BMD): Demographic and other baseline data. Neuromuscular Disorders. 18(9-10). 823–823. 5 indexed citations

14.

Kerem, Eitan, Samit Hirawat, S. Armoni, et al.. (2008). Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. The Lancet. 372(9640). 719–727. 290 indexed citations

15.

Finkel, Richard S., Brenda Wong, Kevin M. Flanigan, et al.. (2007). G.P.3.05 Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy (DMD). Neuromuscular Disorders. 17(9-10). 783–783. 7 indexed citations

16.

Kerem, Eitan, Samit Hirawat, S. Armoni, et al.. (2007). 41* PTC124 activity in CF patients carrying stop mutations: results of a phase 2 study. Journal of Cystic Fibrosis. 6. S10–S10. 2 indexed citations

17.

Cloughesy, Timothy F., Emese Filka, John G. Kuhn, et al.. (2003). Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 97(S9). 2381–2386. 88 indexed citations

18.

Rothenberg, Mace L., John G. Kuhn, Larry J. Schaaf, et al.. (2001). Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Annals of Oncology. 12(11). 1631–1641. 32 indexed citations

19.

Phillips, William A. & Gary Elfring. (1977). Effects of colestipol hydrochloride and neomycin sulfate on cholesterol turnover in the rat. Lipids. 12(1). 10–15. 7 indexed citations

20.

Metzler, Carl M. & Gary Elfring. (1972). A computer study of nonlinear standard curves in chemical and biological assays. Journal of Statistical Computation and Simulation. 1(3). 261–271. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact